ProMIS Neurosciences Inc (PMN) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. Despite insider buying and bullish technical indicators, the company's financial performance is significantly negative, with no recent news or analyst ratings to support a positive outlook. The lack of recent trading signals and congress trading data further limits confidence in this stock as a long-term investment.

Technical Analysis

The technical indicators show a bullish trend with MACD positively expanding, RSI indicating overbought conditions at 90.544, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, the pre-market price is down 1.97%, and the stock is trading near its resistance level (R1: 20.565).

Positive Catalysts

Insider buying has increased significantly by 57003.58% over the last month, indicating potential confidence from company insiders.

Neutral/Negative Catalysts

Additionally, there is no recent news, congress trading data, or analyst ratings to support a positive outlook.

Financial Performance

In Q3 2025, revenue remained at 0 with no growth YoY. Net income dropped to -11,580,126 (-224.84% YoY), and EPS fell to -5.93 (-176.91% YoY). Gross margin remained at 0 with no change YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

3 Analyst Rating

Wall Street analysts forecast PMN stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 23.510

Low

Averages

29.33

High

Current: 23.510

Low

Averages

29.33

High

Guggenheim

Eddie Hickman

Buy

downgrade

$6 -> $5

AI Analysis

2025-11-18

Reason

Guggenheim

Eddie Hickman

Price Target

$6 -> $5

AI Analysis

2025-11-18

downgrade

Buy

Reason

Guggenheim analyst Eddie Hickman lowered the firm's price target on ProMIS Neurosciences to $5 from $6 and keeps a Buy rating on the shares. ProMIS Neurosciences' Alzheimer's candidate, PMN310, is rapidly advancing toward key clinical milestones, which keeps the company on track for two pivotal data readouts in 2026, the analyst tells investors following the company's Q3 report.

H.C. Wainwright

Raghuram Selvaraju

initiated

2025-07-14

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

2025-07-14

initiated

Reason

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of ProMIS Neurosciences with a Buy rating and $4 price target. ProMIS is an emerging biotechnology company focused on developing novel therapeutic and vaccine-based approaches to address serious unmet medical needs in neurology, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PMN

Unlock Now

PMN Should I Buy

PMN Should I Buy

Should You Buy ProMIS Neurosciences Inc (PMN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch